Allarity Therapeutics wins Japanese patent for stenoparib diagnostic
The company said Japan's patent office granted a key patent for its stenoparib-specific DRP® companion diagnostic, extending protection in Japan into 2039.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results.
Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development
TARPON SPRINGS, Fla., September 15, 2026 — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) NASDAQ:ALLR, a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that the Japan Patent O…
ALLR - Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development
ALLR - Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development